Jul 11, 2025
Community update Biogen: salanersen (BIIB115) Study

We are pleased to share a community letter Biogen, announcing topline results from the Phase 1 study of salanersen (BIIB115) for SMA.
We are pleased to share a community letter Biogen, announcing topline results from the Phase 1 study of salanersen (BIIB115) for SMA.
We are pleased to share a community letter from Roche, announcing that the European Commission (EC) has approved a new, room- temperature stable tablet formulation of risdiplam.
We are delighted to invite you to read the latest Spinal cord stimulation: A new perspective for SMA research by Rare Revolution Magazine.
We're excited to announce that SMA News Today has featured our 1st International Clinical Care Symposium on SMA, as part of their latest publication!